Join Drs Tania Jain and Jeanne Palmer as they discuss their approach to transplant in myelofibrosis.

Relevant disclosures can be found with the episode show notes on Medscape https://www.medscape.com/viewarticle/999597. The topics and discussions are planned, produced, and reviewed independently of advertisers. This podcast is intended only for US healthcare professionals.

Resources

Myelofibrosis and Survival Prognostic Models: A Journey Between Past and Future https://pubmed.ncbi.nlm.nih.gov/36983189/

DIPSS plus: A Refined Dynamic International Prognostic Scoring System for Primary Myelofibrosis That Incorporates Prognostic Information From Karyotype, Platelet Count, and Transfusion Status https://pubmed.ncbi.nlm.nih.gov/21149668/

Survival Following Allogeneic Transplant in Patients With Myelofibrosis https://pubmed.ncbi.nlm.nih.gov/32384540/

Posttransplant Cyclophosphamide vs Tacrolimus-based GVHD Prophylaxis: Lower Incidence of Relapse and Chronic GVHD https://pubmed.ncbi.nlm.nih.gov/37156098/

A Prognostic Model to Predict Survival After 6 Months of Ruxolitinib in Patients With Myelofibrosis https://pubmed.ncbi.nlm.nih.gov/35130339/

Advances in Pharmacotherapy for Myelofibrosis: What Is the Current State of Play? https://pubmed.ncbi.nlm.nih.gov/38738513/

ACVR1: A Novel Therapeutic Target to Treat Anemia in Myelofibrosis https://pubmed.ncbi.nlm.nih.gov/38201581/

Superior Outcomes With Fludarabine-Busulfan (Flu/Bu) Based Conditioning for Allogeneic Hematopoietic Cell Transplantation in Myelofibrosis - A Comparative Analysis by CIBMTR https://ashpublications.org/blood/article/138/Supplement%201/912/482649/Superior-Outcomes-with-Fludarabine-Busulfan-Flu-Bu

Post-Transplantation Cyclophosphamide-Based Graft-Versus-Host Disease Prophylaxis With Nonmyeloablative Conditioning for Blood or Marrow Transplantation for Myelofibrosis https://pubmed.ncbi.nlm.nih.gov/35158092/

Anti-T-Lymphocyte Globulin Improves GvHD-Free and Relapse-Free Survival in Myelofibrosis After Matched Related or Unrelated Donor Transplantation https://pubmed.ncbi.nlm.nih.gov/38773281/

Donor Types and Outcomes of Transplantation in Myelofibrosis: A CIBMTR Study https://pubmed.ncbi.nlm.nih.gov/38916866/

Assessment of Quality of Life following Allogeneic Stem Cell Transplant for Myelofibrosis https://pubmed.ncbi.nlm.nih.gov/31288096/